Barollo M, Medici V, D'Inca R, Banerjee A, Ingravallo G, Scarpa M et al
The development of long-acting incretin receptor agonists represents a huge step forward in the fight against the twin epidemics of type 2 diabetes mellitus and obesity
They both have the same active ingredient-exenatide-and are most effective when used in collaboration with proper diet and exercise
In animal studies, BPC-157 has shown potential for accelerating tendon healing, reducing inflammation, supporting gut lining repair, and protecting organs
By highlighting these procedural shortcomings, individuals can cast doubt on the validity of the test results and potentially have them invalidated
Their rate of gastrointestinal side effects nearly doubled compared to the group that started at 2 mg and escalated (Jastreboff et al., NEJM 2023)